Compare CHCO & GLUE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CHCO | GLUE |
|---|---|---|
| Founded | 1957 | 2019 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7B | 1.7B |
| IPO Year | 1995 | 2021 |
| Metric | CHCO | GLUE |
|---|---|---|
| Price | $126.47 | $16.87 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 2 | 3 |
| Target Price | ★ $132.50 | $32.00 |
| AVG Volume (30 Days) | 71.2K | ★ 737.5K |
| Earning Date | 04-23-2026 | 05-08-2026 |
| Dividend Yield | ★ 2.87% | N/A |
| EPS Growth | ★ 13.18 | N/A |
| EPS | ★ 2.20 | N/A |
| Revenue | N/A | ★ $123,672,000.00 |
| Revenue This Year | $5.16 | N/A |
| Revenue Next Year | $3.12 | $2.45 |
| P/E Ratio | ★ $57.63 | $72.42 |
| Revenue Growth | N/A | ★ 63.54 |
| 52 Week Low | $113.21 | $4.12 |
| 52 Week High | $133.59 | $25.77 |
| Indicator | CHCO | GLUE |
|---|---|---|
| Relative Strength Index (RSI) | 58.60 | 37.58 |
| Support Level | $119.61 | $14.43 |
| Resistance Level | $128.20 | $18.66 |
| Average True Range (ATR) | 2.16 | 1.07 |
| MACD | 0.29 | -0.29 |
| Stochastic Oscillator | 73.32 | 16.82 |
City Holding Co is a financial holding company. The company conducts its principal activities through its wholly-owned subsidiary, City National Bank of West Virginia (City National). Through the bank, it provides banking, trust and investment management, and other financial solutions through its network of banking offices located in the states of West Virginia, Virginia, southeastern Ohio, and Kentucky. It offers various products and services such as overdraft facilities, savings accounts, credit cards and debit cards, loans for various purposes, investment advisory, securities brokerage, insurance products, and others. The company's business activities are currently limited to one reportable business segment, which is community banking.
Monte Rosa Therapeutics Inc is a clinical-stage biotechnology company that specializes in developing molecular glue degraders (MGDs), a class of small molecule drugs that leverage the body's natural protein destruction mechanisms to selectively degrade therapeutically-relevant proteins. Utilizing the QuEEN platform, the company employ artificial intelligence and proprietary experimental tools to identify target proteins for degradation by MGDs. The company has three programs in clinical development: MRT-6160, a VAV1-directed MGD for immune-mediated diseases; MRT-8102, a NEK7-directed MGD for inflammatory diseases driven by IL-6, and the NLRP3 inflammasome; and MRT-2359, a GSPT1-directed MGD for metastatic castration resistant prostate cancer (mCRPC).